Based on their efficacy toimprove insulin sensitivity, the TZD PPARγligands rosiglitazone and pioglitazone are currently being utilized in clinicalpractice to treat insulin resistance in patients with type 2 diabetes [23, 24]. Here, INS is linked to type 2 diabetes mellitus.